Akkina RK , Rosenblatt JD , Campbell AG , Chen IS , Zack JA . Modeling human lymphoid precursor cell gene therapy in the SCID - hu mouse . Blood . 1994 ; 84 : 1393 - 1398 . Armour KL , Clark MR , Hadley AG , et al . Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities . Eur J Immunol . 1999 ; 29 ( 8 ) : 2613 - 24 . Anderson KC , Kyle RA , Dalton WS , Landowski T , Shain K , Jove R , Hazlehurst L , Berenson J . Multiple Myeloma : New Insights and Therapeutic Approaches . Hematology 2000 ; 147 - 165 . Anttonen A , Heikkila P , Kajanti M , Jalkanen M , Joensuu H . High syndecan - 1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery . Lung Cancer . 2001 Jun ; 32 ( 3 ) : 297 - 305 . Barbareschi M , Maisonneuve P , Aldovini D , Cangi MG , Pecciarini L , Angelo Mauri F , Veronese S , Caffo O , Lucenti A , Palma PD , Galligioni E , Doglioni C . High syndecan - 1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis . Cancer . 2003 Aug 1 ; 98 ( 3 ) : 474 - 83 . Bataille R , Jego G , Robillard N , Barille - Nion S , Harousseau JL , Moreau P , Amiot M , Pellat - Deceunynck C . The phenotype of normal , " reactive and malignant plasma cells . Identification of "" many and multiple myelomas "" and of new targets for myeloma therapy . Haematologica . 2006 Sep ; 91 ( 9 ) : 1234 - 40 . Review . Bernfield M ", Kokenyesi R , Kato M , Hinkes MT , Spring J , Gallo RL , Lose EJ . Biology of the syndecans : a family of transmembrane heparan sulfate proteoglycans . Annu Rev Cell Biol . 1992 ; 8 : 365 - 393 . Beste G , Schmidt FS , Stibora T , Skerra A . Small antibody - like proteins with prescribed ligand specificities derived from the lipocalin fold . Proc . Natl . Acad . Sci . USA . 1999 : 96 , 1898 - 1903 . Bhattacharyya B , Wolff J . Maytansine binding to the vinblastine sites of tubulin . FEBS Lett . 1977 ; 75 : 159 - 162 . Bisping G , Kropff M , Wenning D , Dreyer B , Bessonov S , Hilberg F , Roth GJ , Munzert G , Stefanic M , Stelljes M , Scheffold C , Muller - Tidow C , Liebisch P , Lang N , Tchinda J , Serve HL , Mesters RM , Berdel WE , Kienast J . Targeting receptor kinases by a novel indolinone derivative in multiple myeloma : abrogation of stroma - derived interleukin - 6 secretion and induction of apoptosis in cytogenetically defined subgroups . Blood . 2006 Mar 1 ; 107 ( 5 ) : 2079 - 89 . Epub 2005 Nov 8 . Blattler WA and Chari RVJ . Drugs to Enhance the Therapeutic Potency of Anticancer Antibodies : Antibody - Drug Conjugates as Tumor - Activated Prodrugs . In : Ojima , I . , Vite , G . D . and Altmann , K . - H . , Editors , 2001 . Anticancer Agents - Frontiers in Cancer Chemotherapy , American Chemical Society , Washington , DC , pp . 317 - 338 . Bross PF , Beitz J , Chen G , Chen XH , Duffy E , Kieffer L , Roy S , Sridhara R , Rahman A , Williams G , Pazdur R . Approval summary : gemtuzumab ozogamicin in relapsed acute myeloid leukemia . Clin Cancer Res . 2001 ; 7 : 1490 - 1496 . Carbone A , Gaidano G , Gloghini A , Ferlito A , Rinaldo A , Stein H . AIDS - related plasma - blastic lymphomas of the oral cavity and jaws : a diagnostic dilemma . Ann . Otol . Rhinol . Laryngol . 1999 ; 108 : 95 - 99 . Carlsson J , Drevin H , Axen R . Protein thiolation and reversible protein - protein conjugation . N - succinimidyl - 3 -( 2 - pyridyldithio ) propionate , a new heterobifunctional reagent . Biochem J 1978 ; 173 : 723 - 737 . Carter P . Improving the efficacy of antibody - based cancer therapies . Nat Rev Cancer . 2001 ; 1 : 118 - 129 . Chari RV , Martell BA , Gross JL , Cook SB , Shah SA , Blattler WA , McKenzie SJ , Goldmacher VS . Immunoconjugates containing novel maytansinoids : promising anticancer drugs . Cancer Res . 1992 ; 52 : 127 - 131 . Chari RV , Jackel KA , Bourret LA , Derr SM , Tadayoni BM , Mattocks KM , Shah SA , Liu C , Blattler WA and Goldmacher VS . Enhancement of the selectivity and antitumor efficacy of a CC - 1065 analogue through immunoconjugate formation . Cancer Res . 1995 ; 55 : 4079 - 4084 . Charnaux N , Brule S , Chaigneau T , Saffar L , Sutton A , Hamon M , Prost C , Lievre N , Vita C , Gattegno L . RANTES ( CCL 5 ) induces a CCR 5 - dependent accelerated shedding of syndecan - 1 ( CD 138 ) and syndecan - 4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD 44 . Glycobiology . 2004 Sep 8 [ Epub ahead of print ] Chen BP , Galy A , Kyoizumi S , Namikawa R , Scarborough J , Webb S , Ford B , Cen DZ , Chen SC . Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID - hu mice . Blood . 1994 ; 84 : 2497 - 2505 . Chilosi M , Adami F , Lestani M , Montagna L , Cimarosto L , Semenzato G , Pizzolo G , Menestrina F . CD 138 / syndecan - 1 : a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies . Mod Pathol . 1999 ; 12 : 1101 - 1106 . Clement C , Vooijs , W . C . , Klein , B . , and Wijdenes , J . In : al . SFSe , ed . J . Leukocyte Typing V . Oxford : Oxford University Press ; 1995 : 714 - 715 . Couturier O , Faivre - Chauvet A ; Filippovich IV ; Thedrez P , Sai - Maurel C ; Bardies M ; Mishra AK ; Gauvrit M ; Blain G ; Apostolidis C ; Molinet R ; Abbe JC ; Bateille R ; Wijdenes J ; Chatal JF ; Cherel M ; Validation of 213 Bi - alpha radioimmunotherapy for multiple myeloma . Clinical Cancer Research 5 ( 10 Suppl . ) ( Oct 1999 ) 3165 s - 3170 s . Davies EJ et al . , Blackhall FH , Shanks JH , David G , McGown AT , Swindell R , Slade RJ , Martin - Hirsch P , Gallagher JT , Jayson GC . Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer Clin Cancer Res . 2004 ; 10 ( 15 ) : 5178 - 86 . Dhodapkar MV , Abe E , Theus A , Lacy M , Langford JK , Barlogie B , Sanderson RD . Syndecan - 1 is a multifunctional regulator of myeloma pathobiology : control of tumor cell survival , growth , and bone cell differentiation . Blood . 1998 ; 91 : 2679 - 2688 . Dore JM , Morard F , Vita N , Wijdenes J . Identification and location on syndecan - 1 core protein of the epitopes of B - B 2 and B - B 4 monoclonal antibodies . FEBS Lett . 1998 ; 426 : 67 - 70 . Dowell JA , Korth - Bradley J , Liu H , King SP , Berger MS . Pharmacokinetics of gemtuzumab ozogamicin , an antibody - targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse . J Clin Pharmacol . 2001 ; 41 : 1206 - 1214 . Edinger M , Sweeney TJ , Tucker AA , Olomu AB , Negrin RS , Contag CH . Noninvasive assessment of tumor cell proliferation in animal models . Neoplasia . 1999 ; 1 : 303 - 310 . Gattei V , Godeas C , Degan M , Rossi FM , Aldinucci D , Pinto A . Characterization of Anti - CD 138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan - 1 in human lymphoma cells . Br J Haematol . 1999 ; 104 : 152 - 162 . Hamann PR , Hinman LM , Beyer CF , Lindh D , Upeslacis J , Flowers DA , Bernstein I . An anti - CD 33 antibody - calicheamicin conjugate for treatment of acute myeloid leukemia . Choice of linker . Bioconjug Chem . 2002 ; 13 : 40 - 46 . Han I , Park H , Oh ES . New insights into syndecan - 2 expression and tumourigenic activity in colon carcinoma cells . J Mol Histol . 2004 : 35 ( 3 ) : 319 - 26 . Hideshima T , Catley L , Yasui H , Ishitsuka K , Raje N , Mitsiades C , Podar K , Munshi NC , Chauhan D , Richardson PG , Anderson KC . Perifosine , an oral bioactive novel alkylphospholipid , inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells . Blood 2006 ; 107 ( 10 ) : 4053 - 62 . Hideshima T , Mitsiades C , Tonon G , Richardson PG , Anderson KC . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets . Nat Rev Cancer 2007 ; 7 ( 8 ) : 585 - 98 . Horvathova M , Gaillard , J . - P . , Liutard , J . , Duperray , C . , Lavabre - Bertrand , T . , Bourquard , P et al . In : al . SFSe , ed . Leucocyte Typing V . Oxford : Oxford University Press ; 1995 : 713 - 714 . Kovtun YV , Audette CA , Ye Y , Xie H , Ruberti MF , Phinney SJ , et al . Antibody - drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen . Cancer Res 2006 ; 66 ( 6 ) : 3214 - 21 . Krebs B , Rauchenberger R , Reiffert S , Rothe C , Tesar M , Thomassen E , Cao M , Dreier T , Fischer D , Hoss A et al . High - throughput generation and engineering of recombinant human antibodies . 2001 . J . Immunol . Methods 254 , pp . 67 - 84 . Kupchan SM , Sneden AT , Branfman AR , Howie GA , Rebhun LI , McIvor WE , Wang RW , Schnaitman TC . Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids . J Med Chem . 1978 ; 21 : 31 - 37 . Kyoizumi S , Baum CM , Kaneshima H , McCune JM , Yee EJ , Namikawa R . Implantation and maintenance of functional human bone marrow in SCID - hu mice . Blood . 1992 ; 79 : 1704 - 1711 . Kyoizumi S , Murray LJ , Namikawa R . Preclinical analysis of cytokine therapy in the SCID - hu mouse . Blood . 1993 ; 81 : 1479 - 1488 . Langford JK , Stanley MJ , Cao D , Sanderson RD . Multiple heparan sulfate chains are required for optimal syndecan - 1 function . J Biol Chem . 1998 Nov 6 ; 273 ( 45 ) : 29965 - 71 . Liu C , Tadayoni BM , Bourret LA , Mattocks KM , Derr SM , Widdison WC , Kedersha NL , Ariniello PD , Goldmacher VS , Lambert JM , Blattler WA , Chari RV . Eradication of large colon tumor xenografts by targeted delivery of maytansinoids . Proc Natl Acad Sci U S A . 1996 ; 93 : 8618 - 8623 . McCune JM , Namikawa R , Kaneshima H , Shultz LD , Lieberman M , Weissman IL . The SCID - hu mouse : murine model for the analysis of human hematolymphoid differentiation and function . Science . 1988 ; 241 : 1632 - 1639 . Mennerich D , Vogel A , Klaman I , Dahl E , Lichtner RB , Rosenthal A , Pohlenz HD , Thierauch KH , Sommer A . Shift of syndecan - 1 expression from epithelial to stromal cells during progression of solid tumours . Eur J Cancer . 2004 Jun ; 40 ( 9 ) : 1373 - 82 . Mosmann T . Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays . J Immunol Methods . 1983 ; 65 : 55 - 63 . Munshi NC , Longo DL , Anderson KC . Plasma cell disorders . In : Braunwald E , Fauci AS , Kasper DL , Hauser SL , Longo DL , Jameson JL , editors . Harrison ' s Principles of Internal Medicine . 16 th ed . New York : McGraw - Hill Medical Publishing Division ; 2008 . p . 700 - 7 . Namikawa R , Ueda R , Kyoizumi S . Growth of human myeloid leukemias in the human marrow environment of SCID - hu mice . Blood . 1993 ; 82 : 2526 - 2536 . O ' Connell FP , Pinkus JL , Pinkus GS . CD 138 ( Syndecan - 1 ) , a Plasma Cell Marker Immunohistochemical Profile in Hematopoietic and Nonhematopoietic Neoplasms . Am J Clin Pathol 2004 ; 121 : 254 - 263 . Ojima I , Geng X , Wu X , Qu C , Borella CP , Xie H , Wilhelm SD , Leece BA , Bartle LM , Goldmacher VS and Chari RV . Tumor - specific novel taxoid - monoclonal antibody conjugates . 2002 . J . Med . Chem . 45 , pp . 5620 - 5623 . Olafsen , T , Cheung , CC , Yazaki , PJ , Li L , Sundaresan G , Gambhir SS , Sherman , MA , Williams , LE , Shively , JE , Raubitschek , AA , and Wu , AM . Covalent disulfide - linked anti - CEA diabody allows site - specific conjugation and radiolabeling for tumor targeting applications . 2004 ; Prot . Eng . Design & Selection 17 : 1 : 21 - 27 . Orosz Z , Kopper L . Syndecan - 1 expression in different soft tissue tumours . Anticancer Res . 2001 : 21 ( 1 B ) : 733 - 7 . Padlan , EA . A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand - binding properties . Mol . Immunol . 1991 ; 28 : 489 - 498 . Payne G . Progress in immunoconjugate cancer therapeutics . Cancer Cell . 2003 ; 3 : 207 - 212 . Pegram MD , Lipton A , Hayes DF , Weber BL , Baselga JM , Tripathy D , Baly D , Baughman SA , Twaddell T , Glaspy JA and Slamon DJ . Phase II study of receptor - enhanced chemosensitivity using recombinant humanized anti - p 185 HER 2 / neu monoclonal antibody plus cisplatin in patients with HER 2 / neu - overexpressing metastatic breast cancer refractory to chemotherapy treatment . 1998 . J . Clin . Oncol . 16 , pp . 2659 - 2671 . Rawstron AC , Owen RG , Davies FE , Johnson RJ , Jones RA , Richards SJ , Evans PA , Child JA , Smith GM , Jack AS , Morgan GJ . Circulating plasma cells in multiple myeloma : characterization and correlation with disease stage . Br J Haematol . 1997 ; 97 : 46 - 55 . Remillard S , Rebhun LI , Howie GA , Kupchan SM . Antimitotic activity of the potent tumor inhibitor maytansine . Science . 1975 ; 189 : 1002 - 1005 . Roguska MA , Pedersen JT , Keddy CA , Henry AH , Searle SJ , Lambert JM , Goldmacher VS , Blattler WA , Rees AR , Guild BC . Humanization of murine monoclonal antibodies through variable domain resurfacing . Proc Natl Acad Sci U S A . 1994 ; 91 : 969 - 973 . Ross S , Spencer SD , Holcomb I , Tan C , Hongo J , Devaux B , Rangell L , Keller GA , Schow P , Steeves RM , Lutz RJ , Frantz G , Hillan K , Peale F , Tobin P , Eberhard D , Rubin MA , Lasky LA , Koeppen H . Prostate stem cell antigen as therapy target : tissue expression and in vivo efficacy of an immunoconjugate . Cancer Res . 2002 May 1 ; 62 ( 9 ) : 2546 - 53 . Ross JS , Gray K , Gray G , Worland PJ , Rolfe M . Anticancer Antibodies , Am J Clin Path . ( 4 / 17 / 2003 ) . Sanderson RD , Lalor P , Bernfield M . B lymphocytes express and lose syndecan at specific stages of differentiation . Cell Regul . 1989 ; 1 : 27 - 35 . Sandhu JS , Clark BR , Boynton EL , Atkins H , Messner H , Keating A , Hozumi N . Human hematopoiesis in SCID mice implanted with human adult cancellous bone . Blood . 1996 ; 88 : 1973 - 1982 . Sasaki A , Boyce BF , Story B , Wright KR , Chapman M , Boyce R , Mundy GR , Yoneda T . Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice . Cancer Res . 1995 ; 55 : 3551 - 3557 . Schneider U , van Lessen A , Huhn D , Serke S . Two subsets of peripheral blood plasma cells defined by differential expression of CD 45 antigen . Br J Haematol . 1997 ; 97 : 56 - 64 . Schuurman J , Van Ree R , G . J . Perdok GJ , Van Doorn HR , Tan KY , Aalberse RC , Normal human immunoglobulin G 4 is bispecific : it has two different antigen - combining sites , Immunology 1999 ; 97 : 693 - 698 . Sebestyen A , Berczi L , Mihalik R , Paku S , Matolcsy A , Kopper L . Syndecan - 1 ( CD 138 ) expression in human non - Hodgkin lymphomas . Br J Haematol . 1999 ; 104 ( 2 ) : 412 - 9 . Seftalioglu A , Karakus S . Syndecan - 1 / CD 138 expression in normal myeloid , acute lymphoblastic and myeloblastic leukemia cells . Acta Histochem . 2003 ; 105 : 213 - 221 . Seftalioglu A , Karakus S , Dundar S , Can B , Erdemli E , Irmak MK , Oztas E , Korkmaz C , Yazar F , Cavusoglu I . Syndecan - 1 ( CD 138 ) expression in acute myeloblastic leukemia cells -- an immuno electron microscopic study . Acta Oncol . 2003 ; 42 : 71 - 74 . Senter PD , Doronina S , Cerveny C , Chace D , Francisco J , Klussman K , Mendelsohn B , Meyer D , Siegall CB , Thompson J et al . ( 2002 ) . Cures and regressions of established tumors with monoclonal antibody auristatin conjugates . Abstract # 2062 , American Assoication for Cancer Res . ( San Francisco , CA : American Association for Cancer Res . ) , 414 . Shields RL , Namenuk AK , Hong K , Meng YG , Rae J , Briggs J , Xie D , Lai J , Stadlen A , Li B , Fox JA , Presta LG . . High resolution mapping of the binding site on human IgG 1 for Fc gamma RI , Fc gamma RII , Fc gamma RIII , and FcRn and design of IgG 1 variants with improved binding to the Fc gamma R . J Biol Chem . 2001 ; 276 ( 9 ) : 6591 - 604 . Sievers EL , Larson R . A . , Stadtmauer , E . A . , Estey , E . , Lowenberg , B . , Dombret , H . , Karanes , C . , Theobald , M . , Bennett , J . M . , Sherman , M . L . et al . Efficacy and safety of gemtuzumab ozogamicin in patients with CD 33 - positive acute myeloid leukemia in first relapse . 2001 . J . Clin . Oncol . 19 , pp . 3244 - 3254 . Sievers EL and Linenberger M . Mylotarg : antibody - targeted chemotherapy comes of age . 2001 . Curr . Opin . Oncol . 13 , pp . 522 - 527 . Smith R . , Single chain antibody variable region fragments ; www . stanford . edu / ~ smithr / science / scfv . html ( last updated on May , 2001 ) . Studnicka GM , Soares S , Better M , Williams RE , Nadell R , Horwitz AH . Human - engineered monoclonal antibodies retain full specific binding activity by preserving non - CDR complementarity - modulating residues . Protein Eng . 1994 : 7 ( 6 ) : 805 - 814 . Tai YT , Li XF , Catley L , Coffey R , Breitkreutz I , Bae J , Song W , Podar K , Hideshima T , Chauhan D , Schlossman R , Richardson P , Treon SP , Grewal IS , Munshi NC , Anderson KC . Immunomodulatory drug lenalidomide ( CC - 5013 , IMiD 3 ) augments anti - CD 40 SGN - 40 - induced cytotoxicity in human multiple myeloma : clinical implications . Cancer Res . 2005 Dec 15 ; 65 ( 24 ) : 11712 - 20 . Tassone P , Goldmacher VS , Neri P , Gozzini A , Shammas MA , Whiteman KA , Hylander - Gans LL , Carrasco DR , Hideshima T , Shringarpure R , Shi J , Allam CK , Wijdenes J , Venuta S , Munshi NC , Anderson KC , Cytotoxic activity of the maytansinoid immunoconjugate B - B 4 - DM 1 against CD 138 + multiple myeloma cells , Blood , 2004 , 104 ( 12 ) , pp . 3688 - 3696 . Tolcher AW , Ochoa L , Hammond LA , Patnaik A , Edwards T , Takimoto C , Smith L , de Bono J , Schwartz G , Mays T , Jonak ZL , Johnson R , DeWitte M , Martino H , Audette C , Maes K , Chari RV , Lambert JM , Rowinsky EK . Cantuzumab mertansine , a maytansinoid immunoconjugate directed to the CanAg antigen : a phase I , pharmacokinetic , and biologic correlative study . J Clin Oncol . 2003 ; 21 : 211 - 222 . Urashima M , Chen BP , Chen S , Pinkus GS , Bronson RT , Dedera DA , Hoshi Y , Teoh G , Ogata A , Treon SP , Chauhan D , Anderson KC . The development of a model for the homing of multiple myeloma cells to human bone marrow . Blood . 1997 ; 90 : 754 - 765 . Vogel CW . Preparation of immunoconjugates using antibody oligosaccharide moieties . Methods in Molecular Biology : Bioconjugation protocols strategies and methods . 2004 ; 283 : 087 - 108 . Vooijs WC , Post J , Wijdenes J , Schuurman HJ , Bolognesi A , Polito L , Stirpe F , Bast EJ , de Gast GC . Efficacy and toxicity of plasma - cell - reactive monoclonal antibodies B - B 2 and B - B 4 and their immunotoxins . Cancer Immunol Immunother . 1996 ; 42 : 319 - 328 . Ward , E . S . , D . Gussow , A . D . Griffiths , P . T . Jones , and G . Winter . Binding activities of a repertoire of single immunoglobin variable domains secreted from Escherichia coli . Nature . 1989 . 341 : 544 - 546 . Wargalla UC , Reisfeld RA . Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells . Proc . Natl . Acad . Sci . USA . 1989 ; 86 : 5146 - 5150 . Wijdenes J , Vooijs WC , Clement C , Post J , Morard F , Vita N , Laurent P , Sun RX , Klein B , Dore JM . A plasmocyte selective monoclonal antibody ( B - B 4 ) recognizes syndecan - 1 . Br J Haematol . 1996 ; 94 : 318 - 323 . Wijdenes J , Dore JM , Clement C , Vermot - Desroches C . CD 138 , J Biol Regul Homeost Agents . 2002 Apr - Jun ; 16 ( 2 ) : 152 - 5 . Witzig TE , Kimlinger TK , Ahmann GJ , Katzmann JA , Greipp PR . Detection of myeloma cells in the peripheral blood by flow cytometry . Cytometry . 1996 ; 26 : 113 - 120 . Xie H , Audette C , Hoffee M , Lambert JM , Blattler W . Pharmacokinetics and biodistribution of the antitumor immunoconjugate , cantuzumab mertansine ( huC 242 - DM 1 ) , and its two components in mice . J Pharmacol Exp Ther . 2004 Mar ; 308 ( 3 ) : 1073 - 82 . Yang M , Jiang P , An Z , Baranov E , Li L , Hasegawa S , Al - Tuwaijri M , Chishima T , Shimada H , Moossa AR , Hoffman RM . Genetically fluorescent melanoma bone and organ metastasis models . Clin Cancer Res . 1999 ; 5 : 3549 - 3559 . Yang M , Baranov E , Jiang P , Sun FX , Li XM , Li L , Hasegawa S , Bouvet M , Al - Tuwaijri M , Chishima T , Shimada H , Moossa AR , Penman S , Hoffman RM . Whole - body optical imaging of green fluorescent protein - expressing tumors and metastases . Proc Natl Acad Sci U S A . 2000 ; 97 : 1206 - 1211 . Yang Y , MacLeod V , Dai Y , Khotskaya - Sample Y , Shriver Z , Venkataraman G , Sasisekharan R , Naggi A , Torri G , Casu B , Vlodavsky I , Suva LJ , Epstein J , Yaccoby S , Shaughnessy JD Jr , Barlogie B , Sanderson RD . The syndecan - 1 heparan sulfate proteoglycan is a viable target for myeloma therapy . Blood . 2007 Sep 15 ; 110 ( 6 ) : 2041 - 8 . Epub 2007 May 29 . Yoshitake S , Yamada Y , Ishikawa E , Masseyeff R . Conjugation of glucose oxidase from Aspergillus niger and rabbit antibodies using N - hydroxysuccinimide ester of N -( 4 - carboxycyclohexylmethyl ) - maleimide . Eur J Biochem 1979 ; 101 : 395 - 399 .